Grace Dy, MD, associate professor, Department of Medicine, Roswell Park Cancer Institute, discusses the anticipation of side effects from targeted therapies in clinical trials.
Grace Dy, MD, associate professor, Department of Medicine, Roswell Park Cancer Institute, discusses the anticipation of side effects from targeted therapies in clinical trials.
In phase I, first-in-human studies, side effects are difficult to anticipate. As an example, Dy cites a preclinical trial looking at SMAC-mimetic birinapant, which found that patients may be at risk for hypotension and cardiovascular side effects. Protocols were put in place in early phase trials to monitor patients' blood pressure for six hours, but found that patients did not experience cardiovascular side effects.
Dy also says that when MEK inhibitors were first being developed, it was not anticipated that ocular side effects were a target effect. As researchers recognized this though, Dy says, protocol has been put in place to require baseline ophthalmologic exams for new generation MEK inhibitors.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More